Clinical trial
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
NCT02847559 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
- Lead sponsor
- Northwestern University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 1, 2016
- Completion date
- May 1, 2026
- Enrollment
- 20 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic (malignant) meningioma, atypical meningioma, grade ii meningioma, grade iii meningioma, recurrent meningioma, supratentorial meningioma